WO1988009384A1

WO1988009384A1 - Method of producing cystatin c or modifications hereof and dna-sequence for use when carrying out the method

Info

Publication number: WO1988009384A1
Application number: PCT/DK1988/000082
Authority: WO
Inventors: Anders Grubb; Åke LUNDWALL; Magnus Abrahamson; Henrik DLABØGE
Original assignee: Nordisk Gentofte AS; Novo Nordisk AS
Current assignee: Nordisk Gentofte AS; Novo Nordisk AS
Priority date: 1987-05-22
Filing date: 1988-05-20
Publication date: 1988-12-01
Anticipated expiration: 1989-11-22
Also published as: FI102191B1; NO890260L; NO890260D0; EP0362259B1; JP3011274B2; NO301985B1; AU619750B2; CA1340862C; DE3855078T2; FI895553A0; JPH03501201A; DE3855078D1; FI102191B; ATE135049T1; AU1939988A; DK260987D0; IL86476A; IL86476A0; EP0362259A1; ES2013337A6

Abstract

Cystatin C or a modified cystatin C is produced biosynthetically by culturing microorganisms or cells into which cDNA extracted from human cells and with codons coding for cystatin C or a modified cystatin C is introduced.

Description

Method of producing cystatin C or modifications hereof and DNA-sequence for use when carrying out the method.

The present invention relates to a method of producing cystatin C (previously called

-trace or post -

globulin). The invention also relates to a DNA-sequence and a plasmid as well as a microorganism for use when carrying out the method.

Mature cystatin C is a known protein with 120 amino acids. The amino acid sequence is as follows:

Ser-Ser-Pro-Gly-Lys-Pro-Pro-Arg-Leu-Val-Gly-Gly-Pro-Met- Asp-Ala-Ser-Val-Glu-Glu-Glu-Gly-Val-Arg-Arg-Ala-Leu-Asp- Phe-Ala-Val-Gly-Glu-Tyr-Asn-Lys-Ala-Ser-Asn-Asp-Met-Tyr- Mis-Ser-Arg-Ala-Leu-Gln-Val-Val-Arg-Ala-Arg-Lys-Gln-Ile- Val-Ala-Gly-Val-Asn-Tyr-Phe-Leu-Asp-Val-Glu-Leu-Gly-Arg- Thr-Thr-Cys-Thr-Lys-Thr-Gln-Pro-Asn-Leu-Asp-Asn-Cys-Pro- Phe-His-Asp-Gln-Pro-Mis-Leu-Lys-Arg-Lys-Ala-Phe-Cys-Ser- Phe-Gln-Ile-Tyr-Ala-Val-Pro-Trp-Gln-Gly-Thr-Met-Thr-Leu- Ser-Lys-Ser-Thr-Cys-Gln-Asp-Ala

Native human cystatin C is a mixture of two types differing in that type I has the amino acid sequence Ser-Ser-OHPro-Gly...Ala, while type II, called 3-des-OH- cystatin C, has the following sequence: Ser-Ser-Pro- Gly...Ala (1). Thus, the two types only differ in the third amino acid residue. As the relative ratio between the two types may vary somewhat, dependent on the origin of the preparations and the extraction method, the biological activity of the preparations may also vary somewhat.

Cystatin C prepared according to the invention is of the type 3-des-OH-cystatin C and thus is considered to have constant activity.

As is known from the literature, cystatin C is an efficient inhibitor for cystein-proteinases, i.a. papain and cathepsin B.

Cystein-proteinases participate in the intracellular catabolism of proteins and peptides, in the proteolytical conversion of prohormonβs, in the extracellular degradation of collagen and in the penetration of normal tissue with malignant cells.

As cystatin C inhibts cystein-proteinases which accelerate cancer growth or metastasis-formation, it is a potential cancer-inhibiting agent.

Furthermore, cystatin C possesses antiviral and possibly antibacterial activity.

Cystein-proteinases, e.g. chymopapain, may be used for treatment of slipped disc. If these cystein-proteinases diffuse into the cerebrospinal fluid, cerebral hemorrhage will occur as a serious side-effect of the therapeutic treatment of slipped disc. As cystatin C inhibits such side-effect, it has therapeutic use in this connection.

Particularly important is the activity of cystatin C to counteract hereditary inclination to cerebral hemorrhage with amyloidosis. It is deposited as amyloid in the arterial walls. The metabolism of cystatin C in this decease which attacks young people is changed, and the sequence for deposited cystatin C deviates at one position from what originally is described regarding cystatin C isolated from people without the decease. In certain types of hereditary cerebral hemorrhage cystatin C is precipitated after splitting off the 10 amino-terminal amino acids in the form of an amyloid in the cerebral arteries which burst. In case of these types of hereditary cerebral hemorrhage a cystatin C molecule is present which at position 68 has a glutamine acid residue instead of a leucine residue.

In the decomposition of collagen in tissue participate i.a. cystein-proteinases, and cystatin C may therefore probably inhibit such decomposition of tissue.

The cystatin C amino acid sequence isolated from human urine has been characterized and appears to be somewhat homologous to c-Ha-ras oncogene products.

The invention is based on the use of a novel DNA- sequence containing codons which code for cystatin C or modifications thereof.

One embodiment of the invention relates to a DNA-copy or a cDNA-sequence formed on the basis of human cells or placenta. Thus, the invention also relates to such DNA- sequence, the structure of which is stated in claim 2.

Further, the invention relates to modified cystatin C, in which one or more amino acids at positions 5-17, 55- 59 and/or 68 have been replaced by another amino acid. An example of such modified cystatin C is a derivative in which Leu at position 68 is changed to Gln.

The invention also relates to a method of producing biosynthetic cystatin C or a modified cystatin C. In such a method a host organism is used, such as bacterium, a yeast cell or a mammal cell line, in which a vector is included, such as a plasmid having the structure suited for expressing cystatin C or a modified cystatin C.

The DNA-sequence in question is inserted together with signal sequences, promotors etc in a plasmid incorporated in the microorganism which is subsequently cultured in a manner known per se.

In the method according to the invention a host organism containing a DNA-sequence coding for cystatin C is cultured in a substrate, the cystatin C formed subsequently being extracted from the culture medium. The preferred host organism is E. coli, but in principle any microorganism may be used, including yeast cells such as Saccharomyces Cerevisiae, or culturing can proceed by means of mammalian cells.

The cystatin C formed is extracted from the culture medium in a manner known per se, e.g. by extraction by way of solvents and purification by chromatography. Affinity chromatography with monoclonal or polyclonal anti-body substances has turned out particularly suited for isolating cystatin C in pure state.

Isolation and analysis of cDNA clones have been effected by screening recombinant phages. Thus λ gtll cDNA library from human placenta and liver mRNA have been used. Screening was at a density of 50.000 plaques pr. 130 mm petri-dishes with affinity-purified anti-body substance by a method according to Young and Davis. Bound antibody substance was demonstrated by alkaline phosphatase- conjugated anti-substance (Promega Bioteknik).

λ-phages produced by the plate lysat method were isolated by centrifugation in a CsCl gradient. DNA was extracted by standard methods. A mixed olignonucleotide probe being specific for cystatin C was hybridized to the product of phage DNA reacted with EcoRI in a Southern blot experiment. Hybridized cDNA insertion was ligated in EcoRI-linearized pϋC18 plasmid vectors which were then used for transforming E. coli JMB83 cells. Plasmids were produced by alkaline lysis method. DNA- sequencing of insertions, the sub-clone in Ml3mp8, was carried out using a modified dideoxy-chain terminator technique.

In the following the invention is described by way of examples.

Example 1

cDNA library from human cells from liver, prostata and placenta were screened for cystatin C coding clones.

About 1.2 x10⁶ recombinants of liver-cells and 3 x 10⁵ recombinants from prostata cells were screened with anti-substances and a mixed oligonucleotide probe. The result of this screening was negative. On the other hand screening of 6 x 10⁵ recombinants of placenta cells yielded nine clones which reacted with the antisubstance.

Three of these clones, designated C5, C6a and C12 respectively, were used in the following. Their inserts of 800, 800 and 700 base pairs, respectively, were specifically hybridized by Southern blot experiments to a mixed ologonucleotide, constructed from protein-sequence-data.

By sequencing inserts from clones C6a and C12, the subclone in EcoRI-cut Ml3mp8, it was disclosed that the inserts shared the same 3'-sequence, containing the polyadenyl-ring signal AATAAA.

The entire sequence of both strings of the clone C6a cDNA insert was determined by sequencing randonmnly overlapping fragments, the sub-clone in M13mp8. Each nucleotide was determined on an average 5.63 times. Data achieved by sequencing cDNA inserts of clones C6a and C12 from the ends revealed that the sequence of C12 inserts starts at position 91 of the C6a, see fig. 1.

The C6a insert contains 777 base pairs, including 77 base pairs of 5'-non-coding sequence and 262 base pairs of 3'-non-coding sequence. The poladenyl signal AATAAA at position 756-761 is succeeded by 15 nucleotides. A possible translation initiation in agreement with the sequence discovered by Kozak is found 6 bp downstream of a stop codon. Initiation at this position and translation stop at the TAG-code at positions 516-518 will finally result in a 120 amino acid long cystatine C with a signal sequence of 26 amino acid residues. The protein in question will be identical with cystatin C, isolated from urine.

Fig. 1 below illustrates a sequencing strategy for human cystatin C cDNA-inserts. Inserts of the clones C12 and C6a were sequenced from their ends by the chainterminator-method. A "shotgun" sequencing-analysis technique was used for sequencing both DNA-strings of C6a inserts. The horizontal arrows indicate the direction and extension of each sequencing analysis. The protein-coding area for inserted C6a is boxed and the hatched part indicates the area which codes for mature protein.

The DNA-structure coding for cystetin C comprises nucleotides derived from amino acid sequence for the clone C6a cDNA which codes for human precystatin C. The numbering of the nucleotid sequence starts at the first nucleotide and proceeds in the direction from 5' to 3'.The numbering of the amino acid starts with the first amino acid in the mature protein. The amino acid substituted in the cystatin C fragment deposited as amyloid in patients suffering from hereditary cerebral hemorrhage with amyloidosis is boxed. The Kozakinitiation and the polyadenyl-ring signal are under- lined.

Example 2

Cytoplasmatic expression of methionin extended Cystatin C in E.colis

The plasmid pUC18/C6a containing the cDNA sequence for Cystation C was cut by the restriction enzymes Ncol/Hindlll, whereafter the plasmid fragment was purified. A synthetic DNA linker containing the code sequence for the amino acid methionin and the approx. first 40 bases of mature Cystatin C were subsequently introduced between the Ncol and the Hindlll sites (fig. 2). Instead of the codons occurring in the cDNA of cystatin C codons were used in the linker which result in high protein yield in E.coli. This plasmid was cut by the restriction enzymes Clal/EcoRI, whereafter a fragment of about 600 by containing the code sequence for methionin-extended Cystatin C was purified.

The plasmid pHD162 containing a synthetic promotor and Shine and Dalgarno sequence was cut by the restriction enzymes Clal/EcoRI, whereafter the plasmid fragment was purified. This plasmid fragment was subsequently combined with the above 600 bp fragment to form the Cystatin C expression plasmid pHD262 (coding for methionin Cystatin C) (fig. 3). E.coli MC1061 containing the above expression plasmid was cultured as described below. Example 3

Periplasmatic expression of Cystatin C in E.coli:

The plasmid pUC18/C6a mentioned in example 2 was cut by the restriction enzymes Ncol/Hindlll, whereafter the plasmid fragment was purified. A synthetic DNA linker containing the code sequence for Outer membrane protein A (OmpA) from E.coli and the first approx. 40 bases of mature Cystatin C were subsequently inserted between the Neol and Hindlll sites. Optimal E.coli codons were used. This plasmid was subsequently cut by the restriction enzymes Clal/EcoRI, whereafter a fragment of about 700 bp containing the code sequence for the OmpA signal peptide and Cystatin C were purified.

The above fragment was then introduced in an expression plasmid containing the λPR promoter, an optimal Shine and Dalgarno sequence, the polylinker region from the plasmide pUC18 and the temperature sensitive CI repressor gene from λ. The plasmid pHD313 (fig. 4) hereby formed was then introduced in E.coli MC1061. The expression of Cystatin C and purification of Cystatin C were carried out as herein described.

Example 4

Periplasmatic expression of cystatin C in E.coli:

The plasmid pUC18 was cut by Apal/EcoRI, and a fragment of approx. 680 base pairs was purified and ligated onto a synthetic Apal/Clal linker containing the code sequence for about the first 3 amino acids of precystatin C. The fragment was subsequently introduced into the expression plasmid, mentioned in example 3, containing the temperature inducing λPR promotor. Example 5

Expression of periplasmatic modified Cystatin C in E.coli:

A Hindlll/EcoRI fragment of about 700 bp was isolated from the expression plasmid pHD313 (example 3).The fragment was introduced in M13 MP18 and exposed to in vitro mutagenesis so that the code sequence for Cystatin C was changed to contain one or more of the modifications appearing from table 1 below. After in vitro mutagenesis a number of clones were cultured and sequence determined. Clones with correct sequence were subsequently cut by Clal/EcoRI, whereafter a fragment of about 700 bp was isolated and introduced into the expression plasmid pHD313. The plasmides hereby formed were cultured, and the product purified as described above.

Example 6

Production of Cystatin C on a technical scale by batch fermentation.

E.coli MC1061 pHD 313-1-1, which expresses Cystatin C with correct N-terminal, is cultured on LB petri dish containing ampicilline. A single colony is transferred to a 100 ml shaker flask containing LB medium and 50 mg/1 ampicilline. This is incubated at 30ºC, 200 rpm for 20 hours.

The fermentation is carried out in 10 1 laboratory fermentor under the following conditions: pH = 7.2, aeration = 1 WM, stirring = 1000 rpm and temperature = 30°C in the first phase. The medium used consists of yeast extract, casamino acids and various salts.

The fermentor is inoculated with 100 ml culture from the shake flask and the dosing of glucose starts when the biomass contentration is OD_525nm = 5. The feed rate must be 3.5 g glucose/1.h, and it is maintained throughout the process. The formation of Cystatin C is induced by raising the temperature in the fermentor to 40°C in the growth phase (OD_525nm = 50) Cystatin C is formed quickly - 2 hours after the temperature was raised the fermentation is ended by lowering the temperature to 20°C and raising pH to 9.0. The entire fermentation process lasts about 12 hours.

By the process are achieved final concentrations of Cystatin C of approx. 1000 mg/1 (Cystatin C constitutes approx. 10% of the total protein in the cell).

Extraction of Cystatin C

Extraction I of Cystatin C from E.coli

The cell suspension from the fermentation is centrifuged. The cells are resuspended in 20-25% w/w sucrose, 0.1 M EDTA, 0.2M Tris pH 9.0 and are agitated for 20 min. Cells are removed by centrifugation and the pellet is quickly resuspended in 0°C 10mM Tris pH 9 under vigorous agitation for 10 min.

The supernatant herefrom contains Cystatin C from the periplasmatic phase (70% of total extraction by mechanical homogenization).

Extraction II of Cystatin C from E.coli

Cell suspension from fermentation is adjusted to pH = 10.5 with 5M NaOH. After stirring for 20 min. the suspension is centrifuged. The supernatant herefrom contains Cystatin C.

Extraction III of Cystatin C from E.coli

Cell suspension from fermentation is centrifuged and resuspended in 0.5M Tris pH = 10.5. After stirring for 20 min. the suspension is centrifuged. The supernatant herefrom contains Cystatin C. Example 7

The extract is dialyzed against 20 nM ethanolamine pH = 10.0 with a dialyze membrane of the type Spectropor^® (mw cut 3500) and is then subjected to a Q-Sepharose column equilibrated in 20 mM ethanolamine, pH = 10.0. Fractions containing Cystatin C (3-des-OH cystatin C) are combined and concentrated on a filter of the type Diafϊo^®YM2. Then the material is subjected to a column of the type Bio-Gel^®P60, equilibrated in 0.05 M ammonium hydrogen carbonate. Fractions containing Cystatin C are collectede By this isolation procedure the yield is typically 50-60%

Construction of a synthetic gene coding for Cystatin C by using optimal E.coli codons:

It is known from the literature that highly expressed E.coli proteins make the use of certain condons for the individual amino acids. Simultaneously with the production of cDNA for Cystatin C a Cystatin C gene was synthesized on the basis of the published amino acid sequence, the gene contained the codons preferred in highly expressed E.coli proteins. The gene was also modified in such a way as to allow a fusion with the signal sequence from either outer membrane protein A from E.coli or the signal sequence from the fibria- protein K88/99 from E.coli. After synthesis the above gene was step-cloned in the plasmid pUC18. The gene was hereafter isolated and introduced in the expression plasmid mentioned in example 3 in combination with one of the above signal sequences. The plasmid was introduced into E.coli MC1061 and cultured as described above.

OmpA-cystatin C gene with optimal E.coli codons. CG-ATG-AAA-AAA-ACT-GCT-ATC-GCT-ATC-GCT-GTT-GCT-CTG-GCT- GGT-TTC-GCT-ACT-GTT-GCT-CAG-GCT-TCT-TCT-CCT-GGT-AAA-CCG- CCT-CGT-CTG-GTT-GGT-GGT-CCG-ATG-GAC-GCT-TCT-GTT-GAA-GAA- GAA-GGT-GTT-CGT-CGT-GCT-CTG-GAC-TTC-GCT-GTT-GGT-GAA-TAC- AAC-AAA-GCT-GTT-AAC-GAC-ATG-TAC-CAC-TCT-CGT-GCT-CTG-CAG- GTT-GTT-CGT-GCT-CGT-AAA-CAG-ATC-GTT-GCT-GGT-GTT-AAC-TAC- TTC-CTG-GAC-GTT-GAA-CTG-GGT-CGT-ACC-ACC-TGC-ACC-AAA-ACC- CAG-CCG-AAC-CTG-GAC-AAC-TGC-CCG-TTC-CAC-GAC-CAG-CCG-CAC- CTG-AAA-CGT-AAA-GCT-TTC-TGC-TCT-TTC-CAG-ATC-TAC-GCT-GTT- CCG-TGG-CAG-GGT-ACC-ATG-ACC-CTG-TCT-AAA-TCT-ACC-TGC-CAG- GAC-GCT-TAA-TAG

Example 8

Production and isolation of 3-des-OH-cystatin C

Bacteria media containing 3-des-OH-cystatin C were centrifuged and bacteria-free media concentrated on a Diaflo™ YM 2 filter. The concentrated material was dialyzed against 20 mM etanol amine, pH 10.0 in

Spectrapor™ dialysis membrane (mw cutoff 3.500) and subsequently applied to a Q-Sepharose™ column equilibrated in 20 mM etanol amine, pH 10.0. Fractions containing 3-des-OH-cystatin C were pooled and concentrated on a Diaflo™ YM 2 filter. The material was then applied to a Bio-Gel™ column equilibrated in 0.05 M ammonium bicarbonate. Fractions containing 3-des-OH- cystatin C were combined. By this isolation procedure the 3-des-OH-cystatin C yield is typically 50-60%.

Characterization of 3-des-OH-cystatin C:

3-des-OH-cystatin C isolated as described above from culture of pHD 313-transformed E.coli, was physicallychemically characterized with a view to biological activity. The results from the characterization were compared with result from corresponding analysis of human cystatin C.

Analysis with Ouchterlony' s double immune diffusion technique showed that all cystatin C-epitopes recognized by a polyclonal anti-serum raised against human cystatin C are also present in 3-des-OH-cystatin C. Agarose gel electrofores at pH 8.6 and SDS-PAGE under reducing or non-reducing conditions showed that 3-des-OH-cystatin C and human cystatin C are identical as regards charge and molecular weight. Amino acid analysis showed that the amino acid composition in 3-des-OH-cystatin C is almost identical with that of human cystatin C. Automated sequence determination showed that 3-des-OH-cystatin C has the N-terrainal sequence.

SSPGKPPRLVGGPMDASVEEEGV--ALDFAVGEYNKASNDMY at each position identical with that found in human cystatin C (cf. ref. 1) and in addition 100% of the prolin residue at position 3 in 3-des-OH-cystatin C lacked a hydroxyl group. Amino acid analysis of disulfide bound peptides showed that 3-des-OH-cystatin G has disulfide bridges between Cys⁷³-Cys⁸³ and Cys⁷³-Cys⁸³, i.e. the same as is the case in human cystatin C (cf. ref. 15).

Biological activity in 3-des-OH-cystatin C is determined through titration against concentration determined papain. 3-des-OH-cystatin C was 83% active, which is higher than corresponding figures for human cystatin C (55%). The strength of binding 3-des-OH-cystatin C on the cystein proteinases papain (EC 3.4.22.2), cathepsin B (EC 3.4.22.1) and dipeptidyl peptidase I (EC 3.4.14.1) was determined. The equilibrium constant for dissociation of 3-des-OH-cystatin C enzyme complex (< 0=005 nM, 0.50 nM and 3.5 nM) was within the experimental error limit identical with the equilibrium constant for human cystatin C enzyme complex (< 0.005 nM, 0.27 nM and 3.5 nM). Thus physical-chemical characterization and analysis performed of the interaction of 3-des-OH-cystatin with cystein proteinases shows that 3-des-OH-cystatin C has full biological activity and is identical with human cystatin C with the exception that it completely lacks hydroxyl group on residue 3.

Example 9

Therapeutic use of 3-des-OH-cystatin C as a CNS- protective agent at chymopapin-treatment of sciatica

Just before chymopapin treatment of patients with sciatica a molar amount of 3-des-OH-cystatin C three times higher than the molar amount of chymopapin to be used is injected into the cerebrospinal fluid. For example, if 8 mg of chymopapin (the active component of the currently available drugs: Disease^®; Travenol Laboraties Ltd., Thetford, UK and Chymodiactin^®; Smith Laboraties, Inc., Rosemont, IL, U.S.A.) is to be used for intradiscal injection, 12 mg of 3-des-OH-cystatin C is injected into the cerebrospinal fluid. The 3-des-OH- cystatin C might be composed of 5 mg 3-des-OH-cystatin C per ml of sterile physiological saline. This will protect against any side effects due to proteolytic breakdown of nervous tissue caused by improper injection of chymopapain into the cerebrospinal fluid.

Alternatively, if clinical or radiographic signs of improper chymopapain injection into the cerebrospinal fluid are observed at, or after, execution of the intended intradiscal chymopapain injection, a molar amount of 3-des-OH-cystatin C three times higher than the molar amount of chymopapain used, is immediately injected into the cerebrospinal fluid in order to inhibit the tissue-damaging effect of chymopapain. Directly after the injection of 3-des-OH-cystatin C the patient is gently moved in a way which brings about a rapid distribution of the injected solution of 3-des-OH- cystatin C with the cerebrospinal fluid of the patient.

Literature

1. Grubb, A & Löfberg, Lt: Proe. Natl. Acad. Sci. 79, 3024-3027, 1982

2. Abrahamson M, Barrett A J, Salvesen G, Grubb A, J. Biol Chem 1986;261(24):1182-9.

3. Abrahamson M, Ritonja A, Brown M A, Grubb A, Machleidt W, Barrett A, J. Biol Chem 1987;262(20):9688-94.

4. Barrett A J, Biochem Sci 1987;12(5):193-6..

5. Barrett A J, Fritz H, Grubb A, Isemura S, Jarvinen M, Katunuma N, Machleidt W, Muller Esterl W, Sasaki M, Turk V, Biochem J 1986,236(1):312.

6. Buttle D J, Abrahamson M, Barrett A J, Spine 1986;11(7):688-94.

7. Delaisse J M, Eeckhout Y, Vaes G, Biochem Biophys Res. Commun 1984;125(2):441-7.

8. Ford L T, Clin Orthop 1969;67:68-71.

9. Garvin P J, Jennings R B, Smith L, Gesler R M, Chymopapain, Clin Orthop 1965;41:204-23.

10. Grubb A, Jensson 0, Gudmundsson G, Arnason A, Löfberg H, Malm J, N Engl J Med 1984;311(24);1547- 9.

11. Grubb A, Grimsberg V, Grubb A, Acta Neurol Scand 1986;73:309-310.

12. Jensson O, Gudmundsson G, Arnason A, Blöndal H, Petrusdottir I, Thorsteinsson L, Grubb A, Löfberg H, Cohen D, Frangione B, Acta Neurol Scand 1987;76:102-14.

13. Nachemson A L, Rydevik B, Acta Orthop Scand 1988;59(1):56-62.

14. Grubb A; Acta Orthop Scand 1988; 59(1):63-65.

15. Grubb A; Löfberg H & Barrett A.,J FEBS Lett. 170.370-374,1984

Claims

P a t e n t C l a i m s :

1. DNA-sequence c h a r a c t e r i z e d in that it comprises codons which code for cystatin C or modifications hereof.

2. DNA-sequence according to claim 1, c h a r a c t e r i z e d in that it is a DNA-copy or cDNA having the structure

22

GGGCGCAGCGGGTCCTCTCTAT 95

CTAGCTCCAGCCTCTCGCCTGCGCCCCACTCCCCGCGTCCCGCTCCTAGCCGACC ATG GCC GGG CCC CTG CGC

Met Ala Gly Pro Leu Arg -26 -21 155

GCC CCG CTG CTC CTG CTG GCC ATC CTG GCC GTG GCC CTG GCC GTG AGC CCC GCG GCC GGC Ala Pro Leu Leu Leu Leu Ala lle Leu Ala Val Ala Leu Ala Val Ser Pro Ala Ala Gly

-1 215

TCC AGT CCC GGC AAG CCG CCG CGC CTG GTG GGA GGC CCC ATG GAC GCC AGC GTG GAG GAG Ser Ser Pro Gly Lys Pro Pro Arg Leu Val Gly Gly Pro Met Asp Ala Ser Val GLu Glu 1 20 275

GAG GGT GTG CGG CGT GCA CTG GAC TTT GCC GTC GGC GAG TAG AAC AAA GCC AGC AAC GAC Glu Gly Val Arg Arg Ala Leu Asp Phe Ala Val Gly Glu Tyr Asn Lys Ala Ser Asn Asp

40 335

ATG TAG CAC AGC CGC GCG CTG CAG GTG GTG CGC GCC CGC AAG CAG ATC GTA GCT GGG GTG Met Tyr His Ser Arg Ala Leu Gin Val Val Arg Ala Arg Lys Gin He Val Ala Gly Val

60 395

AAC TAG TTC TTG GAC GTG GAG

GGC CGA ACC ACG TGT ACC AAG ACC CAG CCC AAC TTG Asn Tyr Phe Leu Asp Val Glu Leu Gly Arg Thr Thr Cys Thr Lys Thr Gin Pro Asn Leu

80

455 GAC AAC TGC CCC TTC CAT GAC CAG CCA CAT CTG AAA AGG AAA GCA TTC TGC TCT TTC CAG Asp Asn Cys Pro Phe His Asp Gin Pro His Leu Lys Arg Lys Ala Phe Cys Ser Phe Gln

100 515 ATC TAC GCT GTG CCT TGG CAG GGC ACA ATG ACC TTG TCG AAA TCC ACC TGT CAG GAC GCC He Tyr Ala Val Pro Trp Gin Gly Thr Met Thr Leu Ser Lys Ser Thr Cys Gin Asp Ala

120 593

TAG GGGTCTGTACCGGGCTGGCCTGTGCCTATCACCTCTTATGCACACCTCCCACCCCTCTATTCCCACCCCTGGAC

672 TGGTGGCCCCTCCCTTGGGGAAGGTCTCCCATGTGCCTGCACCAGGACACAGACAGAGAAGGCAGCAGGCGGCCTTTG

751 TTGCTCAGCAAGGGGCTCTGCCCTCCCTCCTTCCTTCTTGCTTCTCATAGCCCCGGTGTGCGGTGCATACACCCCCACC 777

TCCTGCAATAAAATAGTAGCATCCCC

or a fraction of this structure.

3. DNA-sequence, c h a r a c t e r i z e d in that it consists of a synthetically produced DNA-sequence coding for cystatin C or modifications thereof.

4. DNA-sequence, c h a r a c t e r i z e d in that it comprises codons which are optimal at expression in microorganisms.

5. Recombinant cystatin C, c h a r a c t e r i z e d in that it consists of 3-des-hydroxy-cystatin C.

6. Modified cystatin C, c h a r a c t e r i z e d in that it has the structure for cystatine C in which one or more amino acids at positions 5-17, 55-59 and/or 68 have been replaced by another amino acid.

7. Modified cystatin C according to claim 6, c h a r a c t e r i z e d in that Leu at position 68 has been changed to Gln.

8. DNA-sequence, c h a r a c t e r i z e d in that it comprises codons coding for a modified cystatin C as stated in claim 6.

9. DNA-sequence, c h a r a c t e r i z e d in that it comprises codones coding for cystatin C with one or more of the following modifications:

Leu⁶⁸→Gln

2. Del.Ser¹-Val¹⁰

3. 1+2 4. Gly¹¹→pos. charged, e.g. Arg

Gly¹¹→neg. charged, e.g. Glu

6. Gly¹¹→strongly hydrofob., e.g. Trp 7. 4. Gly¹¹→Ala¹¹, 5Gly¹¹→ Ser¹¹ 8. Substitution in single amino acids, e.g. a.) Arg⁸→Olu b.) Leu⁹→Arg,Glu c.) Val¹⁰→Arg,Glu d.) Gly¹²→Arg,Glu e.) Pro¹³→Arg,Glu,Trp f.) Arg¹⁴ →Arg,Glu

9. Substitution of the entire region, e.g. Arg⁸-Met¹⁴→

Gly-Gly-Gly-Gly-Gly-Gly-Gly

10 Deletion Arg⁸-Met¹⁴ 11 Cys⁸³→ Gly 12 Cys⁹⁷→ Gly 13 Deletion Asn⁶¹→Ala¹²⁰ 14 Deletion Asp⁸¹→Ala¹²⁰ 15 Deletion lle¹⁰¹→Ala¹²⁰

10. A method of producing biosynthetic cystatin C or a modified cystatin C, c h a r a c t e r i z e d in that a host organism containing a DNA-sequence coding for cystatin C or the modified cystatin C is cultured in a substrate, the cystatin C or modified cystatin C formed subsequently being extracted from the culture.

11. A method according to claim 10, c h a r a c t e r i z e d in that the host organism used is a bacterium, a yeast cell or a mammal cell line.

12. A method according to claim 11, c h a r a c t e r i z e d in that the microorganism used is E.coli or S. cerevisiae.

13. A method according to claim 11 or 12, c h a r a c t e r i z e d in that the DNA-sequence used has the structure stated in claims 2-4 or 8-9.

14. Plasmid for introduction into a host organisme which is used for biosynthetic fermentation of cystatin C, c h a r a c t e r i z e d in that it contains the DNA-structure stated in claims 2-4 or 8-9 as well as promotor and signal sequences etc.

15. Microorganism, c h a r a c t e r i z e d in that it contains a plasmid as stated in claim 14.

16. Therapeutic preparation containing the cystatin C or modified cystatin C produced by the method according to claims 10-13.

17. Therapeutic treatment of brain haemorrhage with cystatin C.

18. Therapeutic treatment or prevention of tissue damaging effect in relation to sciatica.